Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 May 6;401(10387):1474-1476.
doi: 10.1016/S0140-6736(23)00587-1. Epub 2023 Apr 13.

Higher-dose dexamethasone for patients with COVID-19 and hypoxaemia?

Anders Perner  1 , Balasubramanian Venkatesh  2
Affiliations
Comment

Higher-dose dexamethasone for patients with COVID-19 and hypoxaemia?

Anders Perner et al. Lancet. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

AP and BV were investigators on the COVID STEROID 2 trial, which was funded by the Novo Nordisk Foundation. AP receives research funding from the Novo Nordisk Foundation and Sygeforsikringen danmark, and has received honorarium from Novartis for participating on an advisory board. The Department of Intensive Care, Rigshospitalet has received funding for research from Pfizer within the past 3 years and has done contract research for AM-Pharma. BV is supported by a National Health and Medical Research Council Investigator Research Fellowship and has received institutional research support from Baxter.

Comment on

Similar articles

See all similar articles

Cited by

References

    1. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384:693–704. - PMC - PubMed
    1. RECOVERY Collaborative Group Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637–1645. - PMC - PubMed
    1. Abani O, Abbas A, Abbas F, et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet. 2022;400:359–368. - PMC - PubMed
    1. Munch MW, Myatra SN, Vijayaraghavan BKT, et al. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia: the COVID STEROID 2 randomized trial. JAMA. 2021;326:1807–1817. - PMC - PubMed
    1. Granholm A, Kjær MN, Munch MW, et al. Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia. Intensive Care Med. 2022;48:580–589. - PMC - PubMed